- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Cipla Limited — Important, 10-12-2025: Product launch
10-12-2025 | 04:04 pm
10-12-2025 | 04:04 pm
Cipla launches Yurpeak® (tirzepatide) in India for obesity and Type 2 diabetes. This one-weekly injectable, a dual GIP/GLP-1 agonist, is distributed via an agreement with Eli Lilly. Cipla aims to expand nationwide access, making this innovative therapy available across India.
No comments yet. Be the first to comment!